Literature DB >> 7998943

Cell surface-mediated activation of progelatinase A: demonstration of the involvement of the C-terminal domain of progelatinase A in cell surface binding and activation of progelatinase A by primary fibroblasts.

R V Ward1, S J Atkinson, J J Reynolds, G Murphy.   

Abstract

We report that the isolated C-terminal domain of progelatinase A is inhibitory to the activation of this proenzyme by primary skin fibroblast plasma membranes but is unable to inhibit organomercurial-induced self-cleavage and activation. Ligand binding studies demonstrate that fibroblasts stimulated with concanavalin A to activate progelatinase A have a significantly enhanced level of cell surface-associated progelatinase A. Tissue inhibitor of metalloproteinases-2 (TIMP-2), an effective inhibitor of membrane-mediated progelatinase A activation, is able to abolish the enhanced level of cell surface-associated progelatinase A that occurs following stimulation. TIMP-1, a poor inhibitor of membrane activation, is unable to inhibit the cell surface binding of progelatinase A. The enhancement in the binding of 125I-progelatinase A to fibroblasts following concanavalin A stimulation can be blocked by the inclusion of excess C-terminal gelatinase A but not by a truncated form of gelatinase A lacking the C-terminal domain. Scatchard analysis of the binding of 125I-progelatinase A to concanavalin A-stimulated fibroblasts has identified 950,000 gelatinase binding sites per cell with a Kd of 1.3 x 10(-8) M. Analysis of non-stimulated fibroblasts has identified 500,000 sites per cell with a Kd of 2.6 x 10(-8) M. We propose that membrane-mediated activation of progelatinase A involves binding of the proenzyme through its C-terminal domain to the cell surface and that TIMP-2 can inhibit activation by interaction with progelatinase A through the C-terminal domain, thus preventing binding of the proenzyme.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7998943      PMCID: PMC1137481          DOI: 10.1042/bj3040263

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  36 in total

1.  Matrix metalloproteinase 2 from human rheumatoid synovial fibroblasts. Purification and activation of the precursor and enzymic properties.

Authors:  Y Okada; T Morodomi; J J Enghild; K Suzuki; A Yasui; I Nakanishi; G Salvesen; H Nagase
Journal:  Eur J Biochem       Date:  1990-12-27

Review 2.  The tissue metalloproteinase family and the inhibitor TIMP: a study using cDNAs and recombinant proteins.

Authors:  A J Docherty; G Murphy
Journal:  Ann Rheum Dis       Date:  1990-06       Impact factor: 19.103

3.  The activation of human type IV collagenase proenzyme. Sequence identification of the major conversion product following organomercurial activation.

Authors:  W G Stetler-Stevenson; H C Krutzsch; M P Wacher; I M Margulies; L A Liotta
Journal:  J Biol Chem       Date:  1989-01-25       Impact factor: 5.157

4.  Purification and characterization of a bone metalloproteinase that degrades gelatin and types IV and V collagen.

Authors:  G Murphy; C G McAlpine; C T Poll; J J Reynolds
Journal:  Biochim Biophys Acta       Date:  1985-09-20

5.  Analysis of radioligand binding experiments. A collection of computer programs for the IBM PC.

Authors:  G A McPherson
Journal:  J Pharmacol Methods       Date:  1985-11

6.  H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen.

Authors:  I E Collier; S M Wilhelm; A Z Eisen; B L Marmer; G A Grant; J L Seltzer; A Kronberger; C S He; E A Bauer; G I Goldberg
Journal:  J Biol Chem       Date:  1988-05-15       Impact factor: 5.157

7.  Concanavalin A produces a matrix-degradative phenotype in human fibroblasts. Induction and endogenous activation of collagenase, 72-kDa gelatinase, and Pump-1 is accompanied by the suppression of the tissue inhibitor of matrix metalloproteinases.

Authors:  C M Overall; J Sodek
Journal:  J Biol Chem       Date:  1990-12-05       Impact factor: 5.157

8.  Independent expression and cellular processing of Mr 72,000 type IV collagenase and interstitial collagenase in human tumorigenic cell lines.

Authors:  P D Brown; A T Levy; I M Margulies; L A Liotta; W G Stetler-Stevenson
Journal:  Cancer Res       Date:  1990-10-01       Impact factor: 12.701

9.  Human 92- and 72-kilodalton type IV collagenases are elastases.

Authors:  R M Senior; G L Griffin; C J Fliszar; S D Shapiro; G I Goldberg; H G Welgus
Journal:  J Biol Chem       Date:  1991-04-25       Impact factor: 5.157

Review 10.  Type IV collagenases in tumor invasion and metastasis.

Authors:  W G Stetler-Stevenson
Journal:  Cancer Metastasis Rev       Date:  1990-12       Impact factor: 9.264

View more
  12 in total

1.  Filamin A controls matrix metalloproteinase activity and regulates cell invasion in human fibrosarcoma cells.

Authors:  Massimiliano Baldassarre; Ziba Razinia; Nina N Brahme; Roberto Buccione; David A Calderwood
Journal:  J Cell Sci       Date:  2012-05-17       Impact factor: 5.285

2.  A critical role for the membrane-type 1 matrix metalloproteinase in collagen phagocytosis.

Authors:  Hyejin Lee; Christopher M Overall; Christopher A McCulloch; Jaro Sodek
Journal:  Mol Biol Cell       Date:  2006-09-13       Impact factor: 4.138

Review 3.  Control of matrix metalloproteinase catalytic activity.

Authors:  Hyun-Jeong Ra; William C Parks
Journal:  Matrix Biol       Date:  2007-07-07       Impact factor: 11.583

Review 4.  Phagocytosis and intracellular digestion of collagen, its role in turnover and remodelling.

Authors:  V Everts; E van der Zee; L Creemers; W Beertsen
Journal:  Histochem J       Date:  1996-04

Review 5.  Matrix metalloproteinases. Novel targets for directed cancer therapy.

Authors:  A E Yu; R E Hewitt; E W Connor; W G Stetler-Stevenson
Journal:  Drugs Aging       Date:  1997-09       Impact factor: 3.923

6.  Selective regulation of MMP and TIMP mRNA levels in tree shrew sclera during minus lens compensation and recovery.

Authors:  John T Siegwart; Thomas T Norton
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-10       Impact factor: 4.799

7.  Expression of membrane-type 1 matrix metalloproteinase and activation of progelatinase A in human osteoarthritic cartilage.

Authors:  K Imai; S Ohta; T Matsumoto; N Fujimoto; H Sato; M Seiki; Y Okada
Journal:  Am J Pathol       Date:  1997-07       Impact factor: 4.307

8.  Elevation of hemopexin-like fragment of matrix metalloproteinase-2 tissue levels inhibits ischemic wound healing and angiogenesis.

Authors:  April E Nedeau; Katherine A Gallagher; Zhao-Jun Liu; Omaida C Velazquez
Journal:  J Vasc Surg       Date:  2011-09-08       Impact factor: 4.268

9.  Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2.

Authors:  A Pfeifer; T Kessler; S Silletti; D A Cheresh; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

10.  Proteolytic processing of membrane-type-1 matrix metalloproteinase is associated with gelatinase A activation at the cell surface.

Authors:  K Lehti; J Lohi; H Valtanen; J Keski-Oja
Journal:  Biochem J       Date:  1998-09-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.